WO2008005021A1 - Use of crystallin for the modulation of ...,https://www.google.com/patents/WO2008005021A1?cl=tr
WO2014015338A1 - Acetylated crystallin polypeptides and mimetics ...,https://google.com/patents/WO2014015338A1?cl=da
EP2190455A1 - Agents with angiogenic and wound healing activity ...,https://www.google.com/patents/EP2190455A1?cl=sv
EP0985047A2 - Somatic gene therapy to suppress secondary ...,https://www.google.com/patents/EP0985047A2
CA2192468A1 - Alpha b crystallin for use in diagnosis and therapy ...,https://google.com/patents/CA2192468A1?cl=tr
US6200799B1 - Somatic gene therapy to suppress secondary ...,http://www.google.com/patents/US6200799
US20080033053A1 - Cross-Reference To Related Applications ...,http://www.google.com/patents/US20080033053
US20080138353A1 - Alpha b-chrystallin as a therapy for ...,https://www.google.com/patents/US20080138353
US20170065617A1 - Compositions and Methods to Treat Vision ...,https://www.google.com/patents/US20170065617?cl=en_2
EP0537166B1 - Polypeptides hydrosolubles ayant une haute affinite ...,https://google.com/patents/EP0537166B1?cl=da
